Abstract

Malaria elimination in the Greater Mekong Sub-Region is challenged by a rising proportion of malaria attributable to P. vivax. Primaquine (PQ) is effective in eliminating the parasite’s dormant liver stages and can prevent relapsing infections, but it induces severe haemolysis in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, highlighting the importance of testing enzyme activity prior to treatment. A mixed-method study was conducted in south-central Vietnam to explore the factors that affect acceptability of G6PD testing, treatment-seeking behaviors, and adherence to current regimens. The majority of respondents (75.7%) were unaware of the different parasite species and rather differentiated malaria by perceived severity. People sought a diagnosis if suspected of malaria fever but not if they perceived their fevers as mild. Most respondents agreed to take prescribed medication to treat asymptomatic infection (94.1%) and to continue medication even if they felt better (91.5%). Health professionals did not have G6PD diagnostic tools nor the means to prescribe PQ safely. Adherence to treatment was linked to trust in public providers, who were perceived to make therapeutic decisions in the interest of the patient. Greater focus on providing acceptable ways of assessing G6PD deficiency will be needed to ensure the timely elimination of malaria in Vietnam.

Highlights

  • Plasmodium falciparum (P. falciparum) and Plasmodium vivax (P. vivax) are the dominant parasite species causing malaria in humans

  • At the time this study was conducted, malaria diagnostics used by the local health services included finger prick sampling, microscopic examination of giemsa stained blood films, and a conventional rapid diagnostic test (RDT)

  • Routine Glucose-6-Phosphate Dehydrogenase (G6PD) testing was not part of the routine healthcare, some health centers in Bac Ai district participated in G6PD research studies during the study period using the qualitative fluorescent spot test (FST) [46]

Read more

Summary

Introduction

Plasmodium falciparum (P. falciparum) and Plasmodium vivax (P. vivax) are the dominant parasite species causing malaria in humans. Outside of sub-Saharan Africa, a rising proportion of malaria is attributable to P. vivax, with the majority of cases concentrated in the Asia-Pacific region [1,2,3]. Six countries in the Greater Mekong Sub-Region (GMS), including Cambodia, Yunnan province, and the Guangxi Zhuang Autonomous Region of China, Laos, Myanmar, Thailand, and Vietnam, have committed to eliminate malaria by 2030 [8,9]. Regional data from to 2018 demonstrate an overall reduction in malaria incidence by 76% [1]. This is mostly due to a decline in the incidence of P. falciparum, whereas there has been an increase in the proportion of P. vivax in most countries [10,11,12].

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call